Aβ-42 sidechain deamidation at Q15 or N27 modulates protein aggregation and alters microglial cytokines and CD68

Insights

Deamidation of amyloid beta (Aβ) alters its aggregation and reduces microglial activation, impacting Alzheimer's disease (AD) inflammation. This suggests Aβ post-translational modifications are key therapeutic targets for AD.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Immunology

Background:

  • Amyloid beta (Aβ) aggregation into oligomers is central to Alzheimer's disease (AD) pathogenesis.
  • Deamidated Aβ variants show altered aggregation and reduced neurotoxicity, but their impact on microglial function needs further study.
  • Previous work indicated Aβ-42-N27D modified aggregation and reduced microglial reactivity, yet the general effect of Aβ-42 side chain deamidation remained unclear.

Purpose of the Study:

  • To investigate the effects of site-specific Aβ-42 deamidation mutations (Q15E & N27D) on Aβ aggregation.
  • To determine how these deamidated Aβ-42 variants influence microglial immune response and inflammatory cytokine secretion.
  • To explore the potential of Aβ-42 post-translational modifications as therapeutic targets in AD.

Main Methods:

  • Utilized size exclusion chromatography to analyze aggregation profiles of Aβ-42-Q15E and Aβ-42-N27D compared to wild-type (WT).
  • Performed multiplexed cytokine analysis to quantify 8 secreted cytokines from microglial cell cultures.
  • Employed immunocytochemistry to assess CD68 expression in microglial cells.

Main Results:

  • Aβ-42-Q15E and Aβ-42-N27D exhibited distinct aggregation profiles compared to Aβ-42-WT.
  • Both deamidated variants significantly decreased the secretion of inflammatory cytokines (IL-6, IP-10, MIP-1α) relative to Aβ-42-WT.
  • Aβ-42-Q15E and Aβ-42-N27D reduced CD68 expression in microglial cells compared to Aβ-42-WT.

Conclusions:

  • Deamidation of Aβ-42 significantly alters its aggregation dynamics.
  • Aβ-42 deamidation modulates microglial activation and inflammatory signaling pathways relevant to AD.
  • Structural modifications of Aβ-42, including deamidation, represent promising avenues for developing novel AD therapeutics.